JP2020527546A - 治療方法 - Google Patents

治療方法 Download PDF

Info

Publication number
JP2020527546A
JP2020527546A JP2019572724A JP2019572724A JP2020527546A JP 2020527546 A JP2020527546 A JP 2020527546A JP 2019572724 A JP2019572724 A JP 2019572724A JP 2019572724 A JP2019572724 A JP 2019572724A JP 2020527546 A JP2020527546 A JP 2020527546A
Authority
JP
Japan
Prior art keywords
seq
tlr7
peptide
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527546A5 (enExample
Inventor
セレミディス，スタヴロス
エー ブルックス，ダグ
エー ブルックス，ダグ
オ’リアリー，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RMIT University
Adelaide University
Original Assignee
Royal Melbourne Institute of Technology Ltd
University of South Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902545A external-priority patent/AU2017902545A0/en
Application filed by Royal Melbourne Institute of Technology Ltd, University of South Australia filed Critical Royal Melbourne Institute of Technology Ltd
Publication of JP2020527546A publication Critical patent/JP2020527546A/ja
Publication of JP2020527546A5 publication Critical patent/JP2020527546A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019572724A 2017-06-30 2018-06-29 治療方法 Pending JP2020527546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902545A AU2017902545A0 (en) 2017-06-30 A method of treatment
AU2017902545 2017-06-30
PCT/AU2018/050667 WO2019000045A1 (en) 2017-06-30 2018-06-29 METHOD OF TREATMENT

Publications (2)

Publication Number Publication Date
JP2020527546A true JP2020527546A (ja) 2020-09-10
JP2020527546A5 JP2020527546A5 (enExample) 2021-07-29

Family

ID=64740713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572724A Pending JP2020527546A (ja) 2017-06-30 2018-06-29 治療方法

Country Status (6)

Country Link
US (2) US11319343B2 (enExample)
EP (1) EP3645030A4 (enExample)
JP (1) JP2020527546A (enExample)
CN (2) CN119548615A (enExample)
AU (1) AU2018293925B2 (enExample)
WO (1) WO2019000045A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645030A4 (en) * 2017-06-30 2021-04-21 The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin TREATMENT PROCEDURES
WO2022170396A1 (en) * 2021-02-12 2022-08-18 ViraLok Therapeutics Pty Ltd Agents and methods for therapy and prophylaxis
CN114532296B (zh) * 2021-12-14 2023-12-15 首都医科大学附属北京同仁医院 NOX2基因缺陷rd1小鼠模型及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
JP2011529967A (ja) * 2008-08-04 2011-12-15 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体７発現の調節
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP2015532097A (ja) * 2012-09-29 2015-11-09 ダイナバックス テクノロジーズ コーポレイション ヒトＴｏｌｌ様受容体阻害剤およびその使用方法
US20170130228A1 (en) * 2014-06-20 2017-05-11 Yale University Compositions and methods to activate or inhibit toll-like receptor signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2050762A3 (en) * 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
EA201291357A1 (ru) * 2010-06-16 2013-11-29 Дайнэвокс Текнолоджиз Корпорейшн Способы лечения с применением ингибиторов tlr7 и/или tlr9
US10370451B2 (en) * 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
EP3645030A4 (en) * 2017-06-30 2021-04-21 The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin TREATMENT PROCEDURES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
JP2011529967A (ja) * 2008-08-04 2011-12-15 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体７発現の調節
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP2015532097A (ja) * 2012-09-29 2015-11-09 ダイナバックス テクノロジーズ コーポレイション ヒトＴｏｌｌ様受容体阻害剤およびその使用方法
US20170130228A1 (en) * 2014-06-20 2017-05-11 Yale University Compositions and methods to activate or inhibit toll-like receptor signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL IMMUNOLOGY, 2013, VOL.25, NO.7, PP.413-422, JPN6022029336, ISSN: 0005185646 *
NATURE COMMUNICATIONS, 2017.07, VOL.8, NO.69, PP.1-17, JPN6022029340, ISSN: 0005005979 *

Also Published As

Publication number Publication date
EP3645030A4 (en) 2021-04-21
CN119548615A (zh) 2025-03-04
CN111417401A (zh) 2020-07-14
EP3645030A1 (en) 2020-05-06
AU2018293925A1 (en) 2020-01-16
US20200216494A1 (en) 2020-07-09
US11319343B2 (en) 2022-05-03
WO2019000045A1 (en) 2019-01-03
AU2018293925B2 (en) 2024-06-13
US20220213143A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
Kawasaki et al. Recognition of nucleic acids by pattern‐recognition receptors and its relevance in autoimmunity
To et al. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy
US12102691B2 (en) Methods for efficient delivery of therapeutic molecules in vitro and in vivo
US10696710B2 (en) Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
EP3030571B1 (en) Peptides capable of reactivating p53 mutants
KR102612226B1 (ko) 유전적으로 암호화가능한 바이오센서용 강력한 저분자 결합 압타머를 생성하기 위한 시험관내 선별법을 이용한 생물학적 rna 스캐폴드의 사용
US20220213143A1 (en) Method of treatment
Eggleton et al. The therapeutic mavericks: Potent immunomodulating chaperones capable of treating human diseases
JP2020536582A (ja) 遺伝子発現抑制剤
JP7037486B2 (ja) 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用
Sundaram Expression And Function Of Human IkappaBzeta In Lung Inflammation
WO2024145365A2 (en) Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
WO2023077133A2 (en) Controlling homeostatic regulatory circuitry in hypothalamus
Center 2050-084X
Speck-Lascola The role of cyclic-GMP dependent protein kinase during macrophage phagocytosis and gene expression
WO2018190713A1 (en) Inhibitors of lysine methyltransferase for treatment of pain
Lei Biochemical and functional characterization of the mitochondrial immune Signaling protein complex
Ewald Activation of nucleic acid-sensing toll-like receptors requires cleavage by endolysosomal proteases: a mechanism to avoid autoimmunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231031